AB Science's Masitinib Shows 42% 5-Year Survival in ALS Patients
Event summary
- AB Science will present survival data from its masitinib ALS trial at the 2026 ENCALS annual meeting.
- Masitinib treatment achieved a 5-year survival rate of 42.3% from disease onset, double historical standards.
- 52.9% survival rate in patients without complete loss of functionality at baseline.
- 49% of long-term survivors maintained quality of life without mechanical support.
- Presentation titled 'Five-Year Survival of 42% in ALS Patients Treated with Masitinib' scheduled for June 25, 2026.
The big picture
AB Science's data positions masitinib as a potential game-changer in ALS treatment, where survival rates have historically been dismal. The 42% 5-year survival rate represents a significant improvement over standard therapies, potentially reshaping the competitive landscape for neurodegenerative disease treatments. The focus on preserving functional independence could make masitinib particularly attractive to patients and payers alike.
What we're watching
- Clinical Validation
- Whether masitinib's survival benefits can be replicated in larger, confirmatory studies.
- Regulatory Pathway
- The pace at which AB Science advances masitinib through regulatory approvals for ALS.
- Market Differentiation
- How masitinib's quality-of-life preservation compares to existing ALS treatments.